Literature DB >> 24961842

Role of positron emission tomography/computed tomography findings for adjuvant chemotherapy indications in stage T1b-2aN0M0 lung adenocarcinoma.

Shinsuke Sasada1, Yoshihiro Miyata1, Norifumi Tsubokawa1, Takahiro Mimae1, Tomoharu Yoshiya1, Morihito Okada2.   

Abstract

BACKGROUND: This study aimed to determine the significance of the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) images on postoperative adjuvant chemotherapy for lung adenocarcinoma.
METHODS: We assessed recurrence-free interval (RFI) and overall survival (OS) based on SUVmax values derived from preoperative FDG-PET/CT images in 174 consecutive patients with completely resected pathologic stage T1b-2aN0M0 lung adenocarcinoma.
RESULTS: Ninety patients received adjuvant chemotherapy and 84 did not. Adjuvant chemotherapy conferred benefits on RFI and OS when compared with observation (p=0.007 and p=0.004, respectively). Multivariate Cox regression analyses revealed SUVmax as an independent prognostic factor for RFI. RFI and OS were significantly longer for patients who received adjuvant chemotherapy compared with those who did not in the group with SUVmax greater than or equal to 2.6 (p<0.001 and p<0.001, respectively). However, RFI and OS did not differ significantly between such patients in the group with SUVmax less than 2.6 (p=0.421 and p=0.452, respectively).
CONCLUSIONS: Preoperative SUVmax determined from FDG-PET/CT images reflected the effect of adjuvant chemotherapy after complete resection in patients with pathologic stage T1b-2aN0M0 lung adenocarcinoma. Indications for postoperative adjuvant chemotherapy among patients with lung adenocarcinoma might be more precisely determined using SUVmax derived from FDG-PET/CT images together with tumor size.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24961842     DOI: 10.1016/j.athoracsur.2014.04.080

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Kai Obayashi; Seshiru Nakazawa; Seiichi Kakegawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Masahiko Nishiyama; Izumi Takeyoshi
Journal:  Surg Today       Date:  2016-01-19       Impact factor: 2.549

Review 2.  [Progress of Postoperative Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer].

Authors:  Bo Liu; Fengxia Ding; Shuangqiang Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.